Unfractionated (UF) and low-molecular-weight (LMW) heparins are widely used anticoagulants to treat patients presenting with thrombosis.
Patients receiving UF heparin are monitored frequently to prevent over- or underanticoagulation. Monitoring may be performed by an APTT or heparin anti-Xa test for the quantitative determination of the plasma levels of UF heparin.
Download the attached paper for details on implementing the INNOVANCE Heparin assay for treatment of thrombosis patients. Complete the form below to request to speak to a Siemens coagulation expert.
